Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dranitsaris

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Technology Assessment in Health Care|January 14, 1999
A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapyA Ortega, G Dranitsaris, A Puodziunas
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 1, 1995
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetronG Dranitsaris, D Warr, A Puodziunas
The Canadian Journal of Hospital Pharmacy|April 1, 1994
A vancomycin drug use evaluation and economic analysis in a cancer treatment centreG Dranitsaris, N J Pilla, A McGreer
Cancer|January 5, 1999
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysisA Ortega, G Dranitsaris, A L Puodziunas
International Journal of Technology Assessment in Health Care|July 12, 2001
A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitalsG Dranitsaris, D Spizzirri, M Pitre, et al.
Pharmacoeconomics|January 9, 2001
The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approachG Dranitsaris, C J Longo, L D Grossman
European Journal of Cancer Care|September 27, 2014
What is a new drug worth? An innovative model for performance-based pricingG Dranitsaris, K Dorward, R C Owens, et al.
Anti-Cancer Drugs|October 19, 2000
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetateG Dranitsaris, P Leung, J Mather, et al.
Investigational New Drugs|November 20, 2012
Clinical trial design in biosimilar drug developmentG Dranitsaris, K Dorward, E Hatzimichael, et al.
Pharmacoeconomics|December 9, 1994
Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patientsG Dranitsaris, T M Tran, A McGeer, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Technology Assessment in Health Care|January 14, 1999
A clinical and economic evaluation of red blood cell transfusions in patients receiving cancer chemotherapyA Ortega, G Dranitsaris, A Puodziunas
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 1, 1995
A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetronG Dranitsaris, D Warr, A Puodziunas
The Canadian Journal of Hospital Pharmacy|April 1, 1994
A vancomycin drug use evaluation and economic analysis in a cancer treatment centreG Dranitsaris, N J Pilla, A McGreer
Cancer|January 5, 1999
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysisA Ortega, G Dranitsaris, A L Puodziunas
International Journal of Technology Assessment in Health Care|July 12, 2001
A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitalsG Dranitsaris, D Spizzirri, M Pitre, et al.
Pharmacoeconomics|January 9, 2001
The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approachG Dranitsaris, C J Longo, L D Grossman
European Journal of Cancer Care|September 27, 2014
What is a new drug worth? An innovative model for performance-based pricingG Dranitsaris, K Dorward, R C Owens, et al.
Anti-Cancer Drugs|October 19, 2000
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetateG Dranitsaris, P Leung, J Mather, et al.
Investigational New Drugs|November 20, 2012
Clinical trial design in biosimilar drug developmentG Dranitsaris, K Dorward, E Hatzimichael, et al.
Pharmacoeconomics|December 9, 1994
Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patientsG Dranitsaris, T M Tran, A McGeer, et al.
Pageof 5